InNexus Biotechnology, Inc.
IXSBF
$0.00
$0.000.00%
OTC PK
| 03/31/2011 | 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -61.77% | -0.67% | -48.40% | -20.48% | -38.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -69.02% | -35.91% | -63.10% | -16.17% | -39.05% |
| Operating Income | 69.02% | 35.91% | 63.10% | 16.17% | 39.05% |
| Income Before Tax | 63.98% | 44.36% | 37.61% | -17.20% | 14.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.98% | 44.36% | 37.61% | -17.20% | 14.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.98% | 44.36% | 37.61% | -17.20% | 14.80% |
| EBIT | 69.02% | 35.91% | 63.10% | 16.17% | 39.05% |
| EBITDA | 78.18% | 38.02% | 68.54% | 20.16% | 38.14% |
| EPS Basic | 77.12% | 66.67% | 62.18% | 28.50% | 40.23% |
| Normalized Basic EPS | 77.08% | 66.34% | 62.50% | 40.15% | 36.84% |
| EPS Diluted | 77.12% | 66.67% | 62.18% | 28.50% | 40.23% |
| Normalized Diluted EPS | 77.08% | 66.34% | 62.50% | 40.15% | 36.84% |
| Average Basic Shares Outstanding | 59.86% | 67.28% | 66.08% | 48.29% | 35.84% |
| Average Diluted Shares Outstanding | 59.86% | 67.28% | 66.08% | 48.29% | 35.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |